Clinical Trial Update: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of PF-06939999 in participants with advanced or metastatic solid tumors was terminated, with results posted on 2025-01-13.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PF-06939999 (PF-06939999)

Snippet

Sponsor: Pfizer | Conditions: Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2025-01-13